Surf Wiki
Save to docs
general/carbonic-anhydrase-inhibitors

From Surf Wiki (app.surf) — the open knowledge base

Diclofenamide

Chemical compound

Summary

Chemical compound

| Drugs.com = | elimination_half-life =

Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-disulfamoylbenzene class. Dichlorphenamide as a carbonic anhydrase inhibitor is used for the treatment of acute angle closure glaucoma. While Dichlorphenamide does contain two sulfate groups within the structure, it falls under the class of a first generation carbonic anhydrase Inhibitor.

Uses

Diclofenamide was approved in the United States in 1958 as Daranide to treat glaucoma, Subsequently, it was found effective in cases of therapy-resistant epilepsy. In 2015, the medication was approved in the US under the name Keveyis as an orphan drug for the treatment of primary hypokalemic and hyperkalemic periodic paralysis.

Cost

In 2001, diclofenamide had a U.S. list price of $50 for a bottle of 100 pills, and was approved for glaucoma. Merck discontinued diclofenamide when better glaucoma drugs were developed. In 2010, Sun Pharmaceutical Industries bought the rights. In 2015, the F.D.A. approved it as an orphan drug, with 7-year exclusive marketing rights, for periodic paralysis, which the company estimates affects 5,000 people in the U.S. In 2016, Strongbridge Biopharma acquired Sun, which raised the price to $15,001 for 100 pills. The cost of treatment would range from $109,500 to $219,000 a year. Sun gives the drug free to patients who don't have insurance.

References

References

  1. (April 16, 2016). "Dichlorphenaide (Keveyis) for Periodic Paralysis". The Medical Letter.
  2. {{drugs.com. international. diclofenamide.html: Diclofenamide
  3. (August 1968). "Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors". The British Journal of Ophthalmology.
  4. (1978). "Diclofenamide in the treatment of therapy-resistant epilepsy". Acta Neurologica Belgica.
  5. Johnson, Carolyn Y.. (December 18, 2017). "This old drug was free. Now it's $109,500 a year.". Washington Post.
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

carbonic-anhydrase-inhibitors sulfonamides chlorobenzene-derivatives ophthalmology-drugs
Want to explore this topic further?

Ask Mako anything about Diclofenamide — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report